Cas:870196-80-8 4-cyano-4-dodecylsulfanylcarbothioylsulfanylpentanoic acid manufacturer & supplier

We serve Chemical Name:4-cyano-4-dodecylsulfanylcarbothioylsulfanylpentanoic acid CAS:870196-80-8 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

4-cyano-4-dodecylsulfanylcarbothioylsulfanylpentanoic acid

Chemical Name:4-cyano-4-dodecylsulfanylcarbothioylsulfanylpentanoic acid
CAS.NO:870196-80-8
Synonyms:4-cyano-4-dodecylsulfanylcarbothioylsulfanylpentanoic acid
Molecular Formula:C19H33NO2S3
Molecular Weight:403.66600
HS Code:

Physical and Chemical Properties:
Melting point:N/A
Boiling point:576.446ºC at 760 mmHg
Density:1.112 g/cm3
Index of Refraction:
PSA:143.78000
Exact Mass:403.16700
LogP:6.80568

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:NONH for all modes of transpor
Packing Group:


Contact us for information like 4-cyano-4-dodecylsulfanylcarbothioylsulfanylpentanoic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-cyano-4-dodecylsulfanylcarbothioylsulfanylpentanoic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-cyano-4-dodecylsulfanylcarbothioylsulfanylpentanoic acid Use and application,4-cyano-4-dodecylsulfanylcarbothioylsulfanylpentanoic acid technical grade,usp/ep/jp grade.


Related News: The fine and functional chemicals sector provides new growth drivers. 4-cyano-4-dodecylsulfanylcarbothioylsulfanylpentanoic acid manufacturer A key publication in a preclinical model demonstrated rigosertib��s ability to block cellular signaling by targeting RAS effector pathways (Divakar, S.K., et al., 2016: ��A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling.�� Cell 165, 643). 4-cyano-4-dodecylsulfanylcarbothioylsulfanylpentanoic acid supplier Rigosertib is a small molecule that inhibits cellular signaling in cancer cells by acting as a RAS mimetic. Current clinical development of rigosertib is centered upon the therapeutic management of MDS, a heterogeneous group of bone marrow disorders characterized by ineffective hematopoiesis that often develop into acute myeloid leukaemia (AML). 4-cyano-4-dodecylsulfanylcarbothioylsulfanylpentanoic acid vendor Some of Amanpour’s counterparts also offered well-wishes on Monday. 4-cyano-4-dodecylsulfanylcarbothioylsulfanylpentanoic acid factory Some of Amanpour’s counterparts also offered well-wishes on Monday.